Transgene
Market Cap
€139.1m
Last Updated
2020/11/26 19:59 UTC
Data Sources
Company Financials +
Executive Summary
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Share Price & News
How has Transgene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TNG is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TNG's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
5.2%
TNG
3.0%
FR Biotechs
1.1%
FR Market
1 Year Return
-13.8%
TNG
35.5%
FR Biotechs
-2.6%
FR Market
Return vs Industry: TNG underperformed the French Biotechs industry which returned 27.7% over the past year.
Return vs Market: TNG underperformed the French Market which returned -3% over the past year.
Shareholder returns
| TNG | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.2% | 3.0% | 1.1% |
| 30 Day | 18.0% | 12.0% | 15.2% |
| 90 Day | 15.3% | 22.3% | 11.6% |
| 1 Year | -13.8%-13.8% | 35.5%35.5% | -0.6%-2.6% |
| 3 Year | -38.7%-40.2% | -31.8%-31.9% | 16.8%7.1% |
| 5 Year | -32.5%-35.6% | -63.5%-63.7% | 48.9%28.7% |
Long-Term Price Volatility Vs. Market
How volatile is Transgene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
How Much is Transgene's (EPA:TNG) CEO Getting Paid?4 months ago | Simply Wall St
How Much is Transgene's (EPA:TNG) CEO Getting Paid?5 months ago | Simply Wall St
Introducing Transgene (EPA:TNG), The Stock That Slid 70% In The Last Five YearsValuation
Is Transgene undervalued compared to its fair value and its price relative to the market?
2.17x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TNG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TNG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TNG is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: TNG is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TNG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TNG is good value based on its PB Ratio (2.2x) compared to the FR Biotechs industry average (3x).
Next Steps
Future Growth
How is Transgene forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
29.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TNG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: TNG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TNG's is expected to become profitable in the next 3 years.
Revenue vs Market: TNG's revenue (34.5% per year) is forecast to grow faster than the French market (7.3% per year).
High Growth Revenue: TNG's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TNG's Return on Equity is forecast to be low in 3 years time (0.6%).
Next Steps
Past Performance
How has Transgene performed over the past 5 years?
33.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TNG is currently unprofitable.
Growing Profit Margin: TNG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TNG is unprofitable, but has reduced losses over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare TNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).
Return on Equity
High ROE: TNG has a negative Return on Equity (-8.83%), as it is currently unprofitable.
Next Steps
Financial Health
How is Transgene's financial position?
Financial Position Analysis
Short Term Liabilities: TNG's short term assets (€57.4M) exceed its short term liabilities (€23.6M).
Long Term Liabilities: TNG's short term assets (€57.4M) exceed its long term liabilities (€21.9M).
Debt to Equity History and Analysis
Debt Level: TNG's debt to equity ratio (36%) is considered satisfactory.
Reducing Debt: TNG's debt to equity ratio has reduced from 115% to 36% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TNG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TNG has less than a year of cash runway if free cash flow continues to grow at historical rates of 14% each year.
Next Steps
Dividend
What is Transgene current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TNG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TNG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TNG's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.8yrs
Average management tenure
CEO
Philippe Archinard (61 yo)
15.92yrs
Tenure
€1,411,000
Compensation
Dr. Philippe Archinard, Ph.D., has been the Chairman of Transgene SA since June 17, 2010 and its Chief Executive Officer since December 6, 2004. Dr. Archinard serves as a Scientific Director of Mérieux All...
CEO Compensation Analysis
Compensation vs Market: Philippe's total compensation ($USD1.68M) is above average for companies of similar size in the French market ($USD479.20K).
Compensation vs Earnings: Philippe's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 15.92yrs | €1.41m | 0.14% € 193.4k | |
| Deputy CEO & VP of Quality | 6.83yrs | €317.00k | no data | |
| CFO & VP of Finance | 6.83yrs | no data | no data | |
| Director of Investor Relations | 12.83yrs | no data | no data | |
| VP, General Counsel & Corporate Secretary | 4.67yrs | no data | no data | |
| Director of Corporate Communications & IR | no data | no data | no data | |
| Vice President of Strategic Alliance | no data | no data | no data | |
| Head of Preclinical Regulatory Laboratory | 15.58yrs | no data | no data | |
| Executive VP and VP of Research & Development | 6.17yrs | no data | no data | |
| Chief Medical Officer | 4.67yrs | no data | no data | |
| Executive Officer | no data | no data | no data | |
| Executive Officer | no data | no data | no data |
6.8yrs
Average Tenure
55yo
Average Age
Experienced Management: TNG's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 15.92yrs | €1.41m | 0.14% € 193.4k | |
| Independent Director | 20.83yrs | €37.00k | 0.089% € 123.7k | |
| Honorary Chairman | 0.83yr | no data | 60.14% € 83.6m | |
| Director | 18.83yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.42yrs | €51.00k | no data |
10.4yrs
Average Tenure
62yo
Average Age
Experienced Board: TNG's board of directors are seasoned and experienced ( 10.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Transgene SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Transgene SA
- Ticker: TNG
- Exchange: ENXTPA
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €139.071m
- Shares outstanding: 83.68m
- Website: https://www.transgene.fr
Number of Employees
Location
- Transgene SA
- 400 Boulevard Gonthier d’Andernach
- Parc d’Innovation – CS80166
- Illkirch-Graffenstaden
- Alsace
- 67405
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TGNA | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Mar 1998 |
| TNG | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Mar 1998 |
| TRGN.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Mar 1998 |
| 0OCQ | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Mar 1998 |
| TNGP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Mar 1998 |
Biography
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company’s lead clinical-stage prog...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 19:59 |
| End of Day Share Price | 2020/11/26 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.